Compare Novo Nordisk A/S (NVO) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Virgin Galactic Holdings, Inc. — how do they compare? Novo Nordisk A/S trades at $38.15 (market cap $165.31B), while Virgin Galactic Holdings, Inc. trades at $2.95 (market cap $445.69M). The key difference: Novo Nordisk A/S is far larger — about 370.9× Virgin Galactic Holdings, Inc.'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| NVO | SPCE | |
|---|---|---|
Market Cap | $165.31B | $445.69M |
Volume | 11,432,838 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $63.98 | $7.52 |
52-Week Low | $35.29 | $2.17 |
Typical Hold Time | 116 Days | 69 Days |
Enterprise Value | $179.56B | $409.68M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting persistent operational losses and a bearish technical outlook. The company continues to burn cash with negative gross and net profit margins, though recent earnings beats and strong ticket demand for future spaceflights offer a glimmer of hope. Cash flow trends show a gradual improvement, with a projected positive net cash flow of $25 million in 2026.
The outlook remains high-risk, high-reward. The path to profitability hinges on the successful commercial launch of Delta flights in 2027. While analyst sentiment is mixed and significant dilution and debt are concerns, the company's unique position in commercial spaceflight presents a speculative opportunity for investors with a long-term horizon and high risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
